vs
Ultragenyx Pharmaceutical Inc.（RARE）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是BRC Group Holdings, Inc.的1.1倍（$207.3M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs -62.0%，领先110.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -21.9%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -15.4%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
RARE vs RILY — 直观对比
营收规模更大
RARE
是对方的1.1倍
$188.3M
营收增速更快
RARE
高出47.8%
-21.9%
净利率更高
RILY
高出110.0%
-62.0%
两年增速更快
RARE
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $207.3M | $188.3M |
| 净利润 | $-128.6M | $90.3M |
| 毛利率 | — | 79.5% |
| 营业利润率 | -54.7% | 32.3% |
| 净利率 | -62.0% | 47.9% |
| 营收同比 | 25.9% | -21.9% |
| 净利润同比 | 3.5% | 1710.8% |
| 每股收益（稀释后） | $-1.28 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RARERILY
| Q4 25 | $207.3M | $188.3M | ||
| Q3 25 | $159.9M | $215.3M | ||
| Q2 25 | $166.5M | $188.2M | ||
| Q1 25 | $139.3M | $197.2M | ||
| Q4 24 | $164.6M | $241.0M | ||
| Q3 24 | $139.5M | $225.5M | ||
| Q2 24 | $147.0M | $256.0M | ||
| Q1 24 | $108.8M | $263.4M |
净利润RARERILY
| Q4 25 | $-128.6M | $90.3M | ||
| Q3 25 | $-180.4M | $91.1M | ||
| Q2 25 | $-115.0M | $139.5M | ||
| Q1 25 | $-151.1M | $-10.0M | ||
| Q4 24 | $-133.2M | $-5.6M | ||
| Q3 24 | $-133.5M | $-284.4M | ||
| Q2 24 | $-131.6M | $-433.6M | ||
| Q1 24 | $-170.7M | $-49.2M |
毛利率RARERILY
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
营业利润率RARERILY
| Q4 25 | -54.7% | 32.3% | ||
| Q3 25 | -106.9% | 30.4% | ||
| Q2 25 | -64.8% | 5.7% | ||
| Q1 25 | -102.6% | -31.2% | ||
| Q4 24 | -74.3% | -69.2% | ||
| Q3 24 | -94.6% | -36.4% | ||
| Q2 24 | -79.1% | -90.8% | ||
| Q1 24 | -151.9% | -6.1% |
净利率RARERILY
| Q4 25 | -62.0% | 47.9% | ||
| Q3 25 | -112.8% | 42.3% | ||
| Q2 25 | -69.0% | 74.1% | ||
| Q1 25 | -108.5% | -5.1% | ||
| Q4 24 | -80.9% | -2.3% | ||
| Q3 24 | -95.7% | -126.1% | ||
| Q2 24 | -89.5% | -169.4% | ||
| Q1 24 | -156.8% | -18.7% |
每股收益（稀释后）RARERILY
| Q4 25 | $-1.28 | $2.78 | ||
| Q3 25 | $-1.81 | $2.91 | ||
| Q2 25 | $-1.17 | $4.50 | ||
| Q1 25 | $-1.57 | $-0.39 | ||
| Q4 24 | $-1.34 | $-0.01 | ||
| Q3 24 | $-1.40 | $-9.39 | ||
| Q2 24 | $-1.52 | $-14.35 | ||
| Q1 24 | $-2.03 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $421.0M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $-80.0M | $-171.5M |
| 总资产 | $1.5B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RARERILY
| Q4 25 | $421.0M | $226.6M | ||
| Q3 25 | $202.5M | $184.2M | ||
| Q2 25 | $176.3M | $267.4M | ||
| Q1 25 | $127.1M | $138.3M | ||
| Q4 24 | $174.0M | $146.9M | ||
| Q3 24 | $150.6M | $159.2M | ||
| Q2 24 | $480.7M | $236.9M | ||
| Q1 24 | $112.3M | $190.7M |
总债务RARERILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益RARERILY
| Q4 25 | $-80.0M | $-171.5M | ||
| Q3 25 | $9.2M | $-260.5M | ||
| Q2 25 | $151.3M | $-351.7M | ||
| Q1 25 | $144.2M | $-496.8M | ||
| Q4 24 | $255.0M | $-488.2M | ||
| Q3 24 | $346.8M | $-497.6M | ||
| Q2 24 | $432.4M | $-218.3M | ||
| Q1 24 | $140.3M | $228.4M |
总资产RARERILY
| Q4 25 | $1.5B | $1.7B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.5B | $1.8B | ||
| Q3 24 | $1.5B | $2.2B | ||
| Q2 24 | $1.6B | $3.2B | ||
| Q1 24 | $1.3B | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-99.8M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $-100.8M | — |
| 自由现金流率自由现金流/营收 | -48.6% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | $-472.0M | — |
8季度趋势，按日历期对齐
经营现金流RARERILY
| Q4 25 | $-99.8M | $26.2M | ||
| Q3 25 | $-91.4M | $-60.6M | ||
| Q2 25 | $-108.3M | $-25.6M | ||
| Q1 25 | $-166.5M | $184.0K | ||
| Q4 24 | $-79.3M | $-2.7M | ||
| Q3 24 | $-67.0M | $19.5M | ||
| Q2 24 | $-77.0M | $111.5M | ||
| Q1 24 | $-190.7M | $135.4M |
自由现金流RARERILY
| Q4 25 | $-100.8M | — | ||
| Q3 25 | $-92.7M | — | ||
| Q2 25 | $-110.7M | — | ||
| Q1 25 | $-167.8M | — | ||
| Q4 24 | $-79.5M | — | ||
| Q3 24 | $-68.6M | — | ||
| Q2 24 | $-79.0M | — | ||
| Q1 24 | $-193.9M | — |
自由现金流率RARERILY
| Q4 25 | -48.6% | — | ||
| Q3 25 | -58.0% | — | ||
| Q2 25 | -66.5% | — | ||
| Q1 25 | -120.5% | — | ||
| Q4 24 | -48.3% | — | ||
| Q3 24 | -49.2% | — | ||
| Q2 24 | -53.7% | — | ||
| Q1 24 | -178.2% | — |
资本支出强度RARERILY
| Q4 25 | 0.5% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 3.0% | — |
现金转化率RARERILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
